BridgeBio Pharma
BBIO
BBIO
429 hedge funds and large institutions have $14.4B invested in BridgeBio Pharma in 2025 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 155 increasing their positions, 139 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
12% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 139
10% more funds holding
Funds holding: 391 → 429 (+38)
2.29% more ownership
Funds ownership: 96.85% → 99.14% (+2.3%)
Holders
429
Holding in Top 10
22
Calls
$894M
Puts
$162M
Top Buyers
| 1 | +$148M | |
| 2 | +$148M | |
| 3 | +$87.3M | |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$64.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$62.6M |
Top Sellers
| 1 | -$104M | |
| 2 | -$100M | |
| 3 | -$65.6M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$54.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$51.2M |